Assembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to Hold
Assembly Biosciences, Inc. (NASDAQ:ASMB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
A number of other research analysts also recently commented on ASMB. BidaskClub raised Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.
Assembly Biosciences (ASMB) traded down 0.31% during midday trading on Tuesday, hitting $35.07. 92,065 shares of the stock traded hands. Assembly Biosciences has a 12-month low of $10.37 and a 12-month high of $36.31. The firm’s 50 day moving average is $30.21 and its 200-day moving average is $25.01. The stock’s market capitalization is $608.96 million.
ILLEGAL ACTIVITY WARNING: “Assembly Biosciences, Inc. (ASMB) Upgraded by Zacks Investment Research to Hold” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/10/assembly-biosciences-inc-asmb-upgraded-by-zacks-investment-research-to-hold.html.
Hedge funds have recently bought and sold shares of the stock. FNY Partners Fund LP acquired a new position in Assembly Biosciences in the first quarter valued at about $140,000. Nationwide Fund Advisors acquired a new position in Assembly Biosciences in the second quarter valued at about $161,000. Parametric Portfolio Associates LLC acquired a new position in Assembly Biosciences in the first quarter valued at about $226,000. Renaissance Technologies LLC acquired a new position in Assembly Biosciences in the first quarter valued at about $242,000. Finally, Legal & General Group Plc acquired a new position in Assembly Biosciences in the second quarter valued at about $212,000. 72.27% of the stock is owned by institutional investors and hedge funds.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.